CAR-T (Chimeric Antigen Receptor T-cell) therapy has revolutionized treatment for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), particularly in pediatric and young adult patients.
Approved CAR-T Products
Tisagenlecleucel (Kymriah)- approved for patients up to age 25 with B-cell ALL that is refractory or in second or later relapse.
It targets CD19 on B-cells.
Brexucabtagene autoleucel (Tecartus)- Approved for adult patients with relapsed/refractory B-cell ALL.
Complete remission rates typically range from 70-90% in clinical trials
Many patients achieve MRD-negative remissions (minimal residual disease)
Long-term remission is possible, though relapse remains a challenge
The ELIANA trial for tisagenlecleucel showed overall remission rates of 81% in pediatric/young adult patients
Relapse can occur through:
CD19-negative relapse (tumor cells lose the CD19 target)
CAR-T cell dysfunction or loss of persistence Rates vary but roughly 40-50% of patients may eventually relapse
Toxicities include:
Cytokine release syndrome (CRS) – ranging from mild to severe Immune effector cell-associated neurotoxicity syndrome (ICANS)
B-cell aplasia,an expected on-target effect
Cytopenias
CAR-T therapy is typically used after conventional chemotherapy has failed, and often serves as a bridge to allogeneic stem cell transplant in eligible patients, though some data suggests durable remissions without transplant in certain cases.
CAR-T therapy is typically used after conventional chemotherapy has failed, and often serves as a bridge to allogeneic stem cell transplant in eligible patients, though some data suggests durable remissions without transplant in certain cases.